EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19

Pedro Landete, Olga-Adriana Caliman-Sturdza iD, Jose A Lopez-Martin iD, Liliana Preotescu iD, Mihaela-Catalina Luca, Anastasia Kotanidou, Paula Villares, Shirley-Patricia Iglesias, Pablo Guisado-Vasco, Elena-Maria Saiz-Lou, Maria Del Carmen Farinas-Alvarez, Esperanza Merino de Lucas iD und 21 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae227 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Pedro Landete und 32 weiteren Autor:innen. Beteiligte Einrichtung: Pneumology Department, Hospital Universitario La Princesa, Madrid, Spain. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Depsipeptides, Peptides, Cyclic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pharma Mar S.A.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Plitidepsin has shown potent preclinical activity against severe acute respiratory syndrome coronavirus 2 and was generally well tolerated in a phase I trial of hospitalized patients with coronavirus disease 2019 (COVID-19). NEPTUNO, a phase III, multicenter, randomized, controlled trial, was designed to evaluate the efficacy and safety of plitidepsin in the management of moderate COVID-19 in hospitalized adult patients.

Methods

Included patients had documented severe acute respiratory syndrome coronavirus 2 infection, required oxygen therapy, and had adequate organ function. The planned sample size was 609 patients. Patients were randomized 1:1:1 to at least 3 days of dexamethasone plus either plitidepsin (1.5 mg/day or 2.5 mg/day, for 3 days) or standard of care (control). The primary endpoint was the time to sustained withdrawal of supplemental oxygen. Secondary endpoints included time to sustained hospital discharge, clinical status, duration of oxygen support, percentage of patients requiring admission to the intensive care unit, and safety.

Results

After randomizing 205 patients, NEPTUNO was discontinued due to a notable drop in COVID-19–related hospitalizations. Available data suggest a 2-day improvement in the median time to sustained oxygen therapy discontinuation (5 vs 7 days) favoring both plitidepsin arms (hazard ratio, 1.37; 95% confidence interval, .96–1.96; P = .08 for plitidepsin 1.5 mg vs control; hazard ratio, 1.06; 95% confidence interval, .73–1.53; P = .78 for plitidepsin 2.5 mg vs control). Plitidepsin was generally well tolerated.

Conclusions

Despite the trial limitations, these results suggest that plitidepsin may have a positive benefit-risk ratio in the management of patients requiring oxygen therapy. Further studies with plitidepsin, including those in immunosuppressed patients, are warranted. Results from this phase III trial suggest that plitidepsin, a first-in-class antiviral, may have a positive benefit-risk ratio in the management of hospitalized patients requiring oxygen therapy for moderate COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 Drug TreatmentDepsipeptidesPeptides, CyclicHumansMaleFemaleMiddle AgedAgedCOVID-19SARS-CoV-2AdultTreatment OutcomeHospitalizationDexamethasoneAntiviral Agents

Stichwörter der Autor:innen

COVID-19SARS-CoV-2antiviral agentsmarine compoundsplitidepsin

Substanzen

plitidepsinDepsipeptidesPeptides, CyclicDexamethasoneAntiviral Agents

Autor:innen und Institutionen

  • Pneumology Department, Hospital Universitario La Princesa, Madrid, Spain.
  • Research Laboratory, Instituto de Investigación La Princesa (IIS Princesa), Madrid, Spain.
  • Department of Pneumology, Hospital Enfermera Isabel Zendal, Madrid SARS CoV2 Unit, Madrid, Spain.
  • Department of Pneumology, Universidad Autónoma de Madrid, Madrid, Spain.
  • Department of Infectious Diseases, Judetean de Urgenta "Sf. Ioan cel Nou", Suceava, Romania.
  • Deparment of Internal Medicine, University of Suceava, Suceava, Romania.

ORCID-Profile: Olga-Adriana Caliman-Sturdza, Jose A Lopez-Martin, Liliana Preotescu, Esperanza Merino de Lucas, Jose-Miguel Cisneros, Garyfallia Poulakou, Miguel Torralba, Jose Jimeno, Jose-Felipe Varona

Förderung

  • Pharma Mar S.A

Zitieren

APA

Landete, P., Caliman-Sturdza, O. A., Lopez-Martin, J. A., Preotescu, L., Luca, M. C., Kotanidou, A., Villares, P., Iglesias, S. P., Guisado-Vasco, P., Saiz-Lou, E. M., Del Carmen Farinas-Alvarez, M., de Lucas, E. M., Perez-Alba, E., Cisneros, J. M., Estrada, V., Hidalgo-Tenorio, C., Poulakou, G., Torralba, M., Fortun, J., …, & Varona, J. F. (2024). A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae227

Vancouver

Landete P, Caliman-Sturdza OA, Lopez-Martin JA, Preotescu L, Luca MC, Kotanidou A, et al. A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae227

BibTeX
@article{Landete2024,
  author = {Landete, Pedro and Caliman-Sturdza, Olga-Adriana and Lopez-Martin, Jose A and Preotescu, Liliana and Luca, Mihaela-Catalina and Kotanidou, Anastasia and Villares, Paula and Iglesias, Shirley-Patricia and Guisado-Vasco, Pablo and Saiz-Lou, Elena-Maria and Del Carmen Farinas-Alvarez, Maria and de Lucas, Esperanza Merino and Perez-Alba, Eduardo and Cisneros, Jose-Miguel and Estrada, Vicente and Hidalgo-Tenorio, Carmen and Poulakou, Garyfallia and Torralba, Miguel and Fortun, Jesus and Garcia-Ocana, Paula and Lemaignen, Adrien and Marcos-Martin, Miguel and Molina, Maria and Paredes, Roger and Perez-Rodriguez, Maria Teresa and Raev, Dimitar and Ryan, Pablo and Meira, Fernanda and Gomez, Javier and Torres, Nadia and Lopez-Mendoza, Diego and Jimeno, Jose and Varona, Jose-Felipe},
  title = {A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae227}
}
Kostenlos starten →